Fexofenadine is an over-the-counter second-generation antihistamine used in the treatment of various allergic symptoms. It is selective for the H receptor, carries little-to-no activity at off-targets, and does not cross the blood-brain barrier - this is in contrast to previous first-generation antihistamines, such as diphenhydramine, which readily bind to off-targets that contribute to side effects such as sedation. Fexofenadine is the major active metabolite of terfenadine and is administered as a racemic mixture in which both enantiomers display approximately equivalent antihistamine activity.
In the United States, fexofenadine is indicated for the symptomatic treatment of allergic rhinitis in patients ≥2 years old and chronic idiopathic urticaria in patients ≥6 months old. In Canada, fexofenadine carries the same indications but is approved only for patients ≥12 years old. Fexofenadine is also available in combination with pseudoephedrine for the symptomatic treatment of season allergic rhinitis in patients ≥12 years old.
North Carolina Clinical and Translational Research Center, Chapel Hill, North Carolina, United States
Investigational Site Number 392003, Osaka-Shi, Japan
Investigational Site Number 392001, Shinjuku-Ku, Japan
Investigational Site Number 392002, Koganei-Shi, Japan
Lal Clínica Pesquisa E Desenvolvimento Ltda, Valinhos, Sao Paulo, Brazil
TKL Research, Paramus, New Jersey, United States
Veeda Clinical Research Pvt. Ltd.,, Ahmedabad, Gujrat, India
Veeda Clinical Research Pvt. Ltd.,, Ahmedabad, Gujrat, India
Anapharm Inc.,, Sainte-Foy Quebec, Canada
Anapharm Inc.,, Sainte-Foy Quebec, Canada
Pfizer Investigational Site, Kingston, Ontario, Canada
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.